Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TOP V122

Next Previous
Drug Profile

TOP V122

Alternative Names: TOP-V-122

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Topadur Pharma
  • Developer Topadur Pharma; University Hospital Zurich; University of Zurich
  • Class Antiglaucomas; Antihypertensives; Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Nitric oxide donors; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • No development reported Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Inflammatory bowel diseases

Most Recent Events

  • 17 Feb 2026 TOP V122 is still in preclinical development for Colorectal cancer (Prevention) in Switzerland (Topadur Pharma pipeline, February 2026)
  • 17 Feb 2026 TOP V122 is still in preclinical development for Colorectal cancer in Switzerland (Topadur Pharma pipeline, February 2026)
  • 17 Feb 2026 TOP V122 is still in preclinical development for Idiopathic pulmonary fibrosis (Topadur Pharma pipeline, February 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top